









The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 
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Objective:  To provide decision makers with a tool to inform resource allocation 
decisions at the local level, using cardiovascular disease prevention as an example.   
Method:  Evidence from the international literature was extrapolated to estimate the 
health and financial impacts in Central Sydney Area Health Service (CSAHS) of three 
different prevention programs; smoking cessation; blood pressure reduction and 
cholesterol lowering.   The cost-effectiveness analysis framework was reconfigured to 1) 
estimate the risk of CVD in the community using local risk factor data, 2) estimate the 
number of CVD events prevented through investment in preventive programs and 3) 
estimate the local financial flow-on effects of prevention on acute care services.   The 
model developed here estimates an upper bound of what local decision makers could 
spend on preventive programs whilst remaining consistent with their willingness to pay 
for one additional life-year gained. 
Results:  The model predicted that over a five-year period the cumulative impact of the 
three programs has the potential to save 1245 life-years in people aged 40-79 years living 
in CSAHS.  If decision-makers are willing to invest in cost-saving preventive programs 
only, the model estimates that they can spend up $12 per person in the target group per 
year.  However, if they are willing to spend $70,000 per life-year gained, this amount 
rises to $201.  
Conclusions:  Modelling the impact of preventive activities on the acute care health 
system enables us to estimate the amount that can be spent on preventive programs.  The 
model is flexible in terms of its ability to examine these impacts in a variety of settings 
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Despite the increasing number of economic evaluations published every year, there is 
considerable evidence that this information remains under used by health care decision 
makers.
1  This seems to be especially true for decisions made at a local level – rather than 
a central level. One reason for this under use appears to be the difficulty decision-makers 
face in assessing whether the results of the published economic evaluation bear any 
relevance to their own circumstances. 
 
The central aim of this paper is to present a model on cardiovascular disease (CVD) 
prevention that local decision makers can use to extrapolate information from the 
published literature and place it in the context of their local setting.  The use of the model 
will enable decision makers to deal with the sources of variation between the local setting 
and the published study. 
 
Decision makers have to deal with four possible sources of variation between local 
settings and the published literature
2.  These are the: 
i.  prevalence and incidence of the disease;  
ii.  resources used and their prices; 
iii.  local resource constraints and the values placed on health; and 
iv.  comparator used in the published study which may not be relevant to current local 
practice. 
 
Each of these potential sources of variation may lead to marked differences between the 
local setting and the results of the published literature.  The model presented in this paper 
can be used to deal with the first three sources of variation.  Decision makers can then  
 
assess whether the model has provided sufficient information to determine whether the 
fourth source of variation is likely to influence results. 
 
The model will be particularly useful if there is a lack of local information about the 
incremental costs of preventive interventions.  It provides decision-makers with an 
estimate of the upper limit that could feasibly be spent on an intervention whilst 
remaining cost-effective.  
 
The data and results presented here are based on the characteristics of the Central Sydney 
Area Health Service (CSAHS) population but these are used for illustrative purposes 
only.  The model is designed to be readily adaptable to suit other regional population 




The equation below provides the basis for calculating the point at which the cost of a 
preventive intervention is equal to the potential savings made elsewhere in the health care 
system. The intervention is deemed to be cost-effective if the Cost Effectiveness 
Threshold (the incremental amount that decision makers are willing to pay for a positive 
health effect - e.g. life-years gained) is equal to or greater than:  
{ }
{}




      
 
Rearranging gives: 
{ } { } () InterventionCosts Cost EffectivenessThreshold LifeYears Gained Direct HealthCareCosts Avoided ≤× +
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The model presented in this paper provides information on the maximum amount that can 
be spent on an intervention without breaking any predetermined expenditure limits for 
that condition. 
 






Life-years gained:  reP L Y L ××
= ∑       
Where n is the number of individuals in a target group with a modifiable risk factor and to 
whom a preventive intervention can be applied (e.g. the number of people in the 
population who smoke and can be targeted by an anti-smoking campaign);  rit is the 
absolute risk of cardiovascular death for individual i over time period t; eit is the 
effectiveness of the preventive intervention for individual i over period t in reducing the 
risk of cardiovascular death; and PLYL is the number of potential life-years lost due to 
premature cardiovascular death for individual i.  
i Intervention costs: (n   Cp )   ×        






Direct health care costs avoided :    re ××
= ∑       
Where Ca is the cost of acute care, for individual i, over time period t.   For the purposes 





Estimating the cost-effectiveness threshold:  The most common decision rule for 
economic evaluation is to compare the incremental cost-effectiveness ratio with some 
benchmark value.
3  An intervention with an incremental cost-effectiveness ratio below 
this benchmark is considered to be good value for money.   
 
In Australia, the National Health and Medical Research Council (NHMRC) suggest a 
threshold range depending on the strength of the evidence.  If the evidence is strong then 
interventions with an incremental cost-effectiveness ratio of $70,000 or less per life-year 
gained should be recommended
4. 
 
The model allows decision makers to enter their own cost-effectiveness threshold.  For 
illustrative purposes, this paper shows the results for two threshold levels; $0 and 
$70,000.  The former amount imposes a decision rule that the intervention must be cost-
saving and the latter figure is consistent with the NHMRC guidelines.   
 
Estimating the target population (n):  The 1996 census was used to extrapolate 
population and age data for the CSAHS.  The NSW Health Survey
5 provided estimates of  
the proportion of people in the CSAHS who smoke daily, have high blood pressure 
(defined as having a systolic blood pressure of over 140mmHg), have high blood 
cholesterol (defined as having total blood cholesterol to HDL cholesterol ratio of 6:1 or 
higher), or any combination of these risk factors
6.   
 
The results from two other studies
7,8 were applied to the model to obtain an estimate of 
the distribution of severity of high cholesterol and systolic blood pressure levels within 
the population.   
 
 
Estimating the absolute risk of cardiovascular disease (r): The Framingham Heart Study 
equations estimate the absolute risk of cardiovascular (CVD) events.  One such equation 
estimates the total risk of suffering a CVD event that an individual faces over a given 
period of time. A CVD event is described as the following: stroke, myocardial infarction, 
angina pectoris, coronary insufficiency, death from coronary heart disease, congestive 
heart failure and peripheral vascular disease.
9   
 
The Framingham Heart Study equations used in this model calculate the overall risk of a 
CVD event and the risk of CVD related death - based on an individual’s age, systolic 
blood pressure, smoking status, and cholesterol level.  For the purposes of this paper, 
risks are estimated for a five-year period. Recent studies have validated the use of the 
Framingham equations for the population of interest in this paper.
10   
 
The cost of cardiovascular disease (Ca): Published results from Western Australia (WA) 
were used to estimate average hospital, pharmaceutical and medical service costs for 
patients who have suffered a CVD event.
11  The WA cost data were derived from 
longitudinal utilisation records.  Individuals were identified if they were hospitalised, 
used subsidised medical services and/or pharmaceuticals related to CVD. Following 
identification, patient service use was tracked for one year.  
 
Measuring the effectiveness ( ei): The results of three different types of interventions are 
presented in this paper.  Each intervention targets one of three CVD risk factors: high 
blood pressure, high cholesterol and smoking.  Evidence on the effectiveness of 
preventive interventions was derived from systematic reviews available from the  
 
Cochrane Library and the Health Education Authority, London.
12, , 13 14  Each of these 
studies provides evidence of the impact that a preventive intervention has on at least one 
of the relevant CVD risk factors.    Table 4 provides details of the effectiveness of the 
three preventive interventions. 
 
Measuring potential life-years lost and gained: "Years of life lost (YLLs)" is the number 
of potential years of life lost due to premature death.  The study calculated the years of 
life lost due to a death at a given age using the life expectancy at that age in standard life 
tables.
15,16  A 5% discount rate has been applied to years of life lost in the future to 
estimate the net present value of years of life lost.   
 
RESULTS 
ABSOLUTE RISK (r) 
 Table 1 illustrates the estimated probability of a cardiovascular disease event taking 
place over the next five-years for men aged between 40 and 79. For example, a male 
smoker aged 70-79 years, with systolic blood pressure of 180 mmHg and a total 
cholesterol to HDL cholesterol ratio of 6:1 has a 43% risk of suffering a CVD event in 
the next five-years.  A similar exercise was undertaken to estimate the probabilities of 
CVD for women (not shown).  
Table 1– Estimated five-year risk of a cardiovascular disease event for men aged 40–79 
years , by smoking status, systolic blood pressure level and cholesterol level.  
 
180 0.22 0.25 0.28 0.31 0.33 Age 0.34 0.37 0.41 0.43 0.46 180
160 0.18 0.21 0.23 0.26 0.28 70-79 0.28 0.32 0.35 0.38 0.40 160
140 0.14 0.16 0.19 0.21 0.23 0.23 0.26 0.29 0.32 0.34 140
120 0.10 0.12 0.14 0.15 0.17 0.17 0.20 0.23 0.25 0.27 120
180 0.16 0.18 0.21 0.23 0.25 Age 0.25 0.29 0.32 0.35 0.37 180
160 0.12 0.15 0.17 0.19 0.21 60-69 0.21 0.24 0.27 0.30 0.32 160
140 0.09 0.11 0.13 0.14 0.16 0.16 0.19 0.22 0.24 0.26 140
120 0.06 0.08 0.09 0.10 0.12 0.12 0.14 0.16 0.18 0.20 120
180 0.10 0.12 0.14 0.15 0.17 Age 0.17 0.20 0.23 0.25 0.27 180
160 0.07 0.09 0.11 0.12 0.13 50-59 0.14 0.16 0.19 0.21 0.23 160
140 0.05 0.06 0.08 0.09 0.10 0.10 0.12 0.14 0.16 0.18 140
120 0.03 0.04 0.05 0.06 0.07 0.07 0.09 0.10 0.12 0.13 120
180 0.05 0.06 0.07 0.09 0.10 Age 0.10 0.12 0.14 0.16 0.17 180
160 0.03 0.04 0.05 0.06 0.07 40-49 0.07 0.09 0.11 0.12 0.14 160
140 0.02 0.03 0.04 0.04 0.05 0.05 0.07 0.08 0.09 0.10 140
120 0.01 0.02 0.02 0.03 0.03 0.03 0.04 0.05 0.06 0.07 120

































































TARGET POPULATION (n)  
The total number of CSAHS residents aged between 40 and 79 in 1998 was estimated to 
be 157,232, of which 77,515 were male
17.  On the basis of the NSW Health Survey 
results, we estimated the number of men and women in each of the relevant risk factor 
categories.  For example, as shown in Table 2, the model predicts that there are 20 men 
aged between 70 and 79 who smoke, have systolic blood pressure of 180mmHg and a 
total cholesterol to HDL cholesterol ratio of level 6:1  
Table 2– Estimated number of men living in the CSAHS aged 40-79 years by 
smoking status, systolic blood pressure and cholesterol level  - 1998   
 
180 88 340 233 123 39 Age 8 3 12 01 1 3 1 8 0
160 409 1586 1089 575 181 70-79 37 144 93 49 16 160
140 307 1189 558 294 93 32 124 60 32 10 140
120 468 1813 850 449 142 49 189 91 48 15 120
180 98 378 294 155 49 Age 13 48 30 16 5 180
160 456 1766 1370 723 228 60-69 58 226 141 74 23 160
140 428 1657 794 419 132 75 291 133 70 22 140
120 652 2527 1211 639 202 114 444 203 107 34 120
180 88 340 222 117 37 Age 25 99 56 29 9 180
160 410 1589 1036 547 173 50-59 119 461 259 137 43 160
140 612 2373 926 488 154 167 647 216 114 36 140
120 934 3619 1411 745 235 255 987 329 174 55 120
180 67 258 144 76 24 Age 17 67 44 23 7 180
160 311 1204 673 355 112 40-49 81 313 203 107 34 160
140 1146 4440 1061 560 177 366 1418 416 220 69 140
120 1748 6772 1618 854 270 558 2162 634 335 106 120

































































With the information contained in Tables 1 and 2, we estimated the number of expected 
CVD events and deaths over a five-year period by multiplying the absolute risk (r) by the 
estimated number of people in each risk factor category. Continuing the previous 
example, just under nine (0.43*20) CVD events are expected to take place over the next 
five-years amongst the group of 70-79 year old men who smoke, have a systolic blood 
pressure of 180 mmHg and a total cholesterol to HDL cholesterol ratio of 6:1. This 
calculation assumes that there is no change in the prevalence or severity of the risk 
factors during this period. 
 
COST OF ACUTE CARE (Ca) 
Table 3 shows the estimated average cost per person for acute care and follow-up 
management of a CVD event based on results from the WA Linked Data Project.
11  It 
details the estimated first year and annual follow-up costs for individuals who have been 
hospitalised for a CVD event. It is assumed that a hospitalisation for the CVD event 
occurred in the first year and that follow-up treatment is conducted outside the hospital  
 
system. Follow-up costs, after hospitalisation, were extrapolated for a five-year period. 
Costs incurred in years 2 to 5 have been discounted at a rate of 5% per annum and were 
indexed to reflect 2000/01 health prices.
18  
Table 3 – Per person health system cost in the first year and annual follow-up after 
a CVD event 
  Cost of first year ($) Annual follow-up  
costs ($) 
Total cost for 5 
years ($) 
(discounted at 5%) 
Female 6,018  1,290  10,564 
Male 7,860  1,275  12,352 
Source: 11 
 
EFFECTIVENESS OF PREVENTION ( ei)  
Table 4 lists the three interventions used to extrapolate effectiveness data.  The relative 
effectiveness of each intervention is measured in terms of its success compared to the 
control group (as defined by the Cochrane publication).  The three interventions illustrate 
the model’s ability to analyse the impact of interventions that counter any one of three 
CVD risk factors.  It should be noted that the model is able to easily estimate the local 
impact of other types of interventions aimed at reducing smoking rates, lowering 
cholesterol or blood pressure, or any combination of the three. 
Table 4 – CVD prevention interventions modelled and the evidence on effectiveness 
Broad area of 
intervention 
Source Intervention  Result 
Smoking cessation  [12]  Nicotine Replacement 
Therapy (NRT) 
7 % of people quit smoking 
over and above control  group
Reduce blood  [13]  Counselling or education  Reduced average systolic  
 
pressure  interventions with or 
without pharmacological 
treatments  
blood pressure by 3.9mmHg 
in people with hypertension  
Reduce cholesterol  [14]  Counselling (nutritionist 
and trained counsellor) 
Mean absolute reduction of 
0.2 to 0.3 mmol/l reduction in 
total cholesterol.  
 
BASELINE SCENARIO 
Having identified the at-risk population along with the associated absolute risk of a CVD 
event occurring, we estimated the total number of expected CVD events in persons aged 
40 to 79 over the next five-years in CSAHS and the health system costs associated with 
these events (Table 5). 
Table 5 Expected number of CVD events, deaths, life-years lost and associated costs 
over five-years in Central Sydney 
  Females Males  Total 






CVD-related deaths   
498
  
1,090   1,588  






Expected acute care costs (million)  $55.1 $88.2  $143.3
 
 
Overall, 11,703 CVD events are estimated to cost the health system $143.3 million over 
five-years, with over 16,000 potential life-years lost. The figures presented in Table 5 are 
the baseline health impact and health system costs from which potential health and 
economic gains are estimated.  
 
POST INTERVENTION SCENARIO  
 
Table 6 models the health and financial results following the introduction of the three 
preventive interventions for all CSAHS residents aged between 40 and 79 years.  The 
model predicts that over a five-year period, the smoking-cessation program can save 111 
life-years, the blood pressure reduction program 580 and the cholesterol lowering 
program 554 life-years. Table 6 also shows the potential acute care costs that can be 
avoided through intervention.  These estimates have been discounted over a five-year 
period, reflecting the timeframe over which the savings are calculated.   
 
Table 6 also presents the financial results of the three preventive interventions.  If a $0 
threshold is applied to the model (implying that the preventive intervention must be cost-
saving) the total amount that can be spent on the interventions per year ranges between 
$182,000 for the quit smoking campaign to $507,332 for the blood pressure program.  
This would translate to an expenditure of $6 and $12 respectively for each person in the 
target population per year. 
If a $70,000 threshold is applied (implying that the decision maker is willing to pay 
$70,000 per life-year gained), the total amount that can be spent on the programs ranges 
between $1.7 million for the quit smoking program and $8.6 million for the blood 
pressure program.  This translates to a possible annual expenditure of up to $59 and $201 
per person in the target group.  
Table 6: Five-year health and financial results after introduction of interventions 








a  Target population: number of people in 
CSAHS with risk factor 
29,582 42,887  56,430 
b  Health impact -  number of potential life-years 
saved (discounted) 
111 580  554 
c  Financial impact –potential health system 
savings over 5 years (discounted). 
$910,144 $2,536,659  $2,392,324 
When CE threshold 
(e) = $0 
$182,029 $507,332  $478,465 




Where t = time = 5 
years 
 
When CE threshold 
(e) = $70,000 
$1,735,423 $8,624,673  $8,228,968 
Threshold  = $0  $6  $12  $8  f Cost-effective 
intervention 
expenditure per targeted 
person per year 
{d/a} 
Threshold = $70,000  $59  $201  $146 
 
DISCUSSION 
Many health care decisions are taken at a regional level, including resource allocation 
choices in the field of population health.  However, decision makers often face 
uncertainty about the likely impact that such decisions may have on health and resources 
within their local community.  To address this issue, results from the international 
literature, the population characteristics of CSAHS, and Australian health service cost 
data were entered into a model to identify the amount that could be cost effectively spent 
on three CVD prevention interventions in CSAHS with no increase in total health service 
expenditure on CVD management.    
 
 
The model’s flexibility gives it the capacity to be of value to decision-makers in a wide 
range of populations.  The model can be easily modified to (1) produce results for any 
population size, (2) incorporate costs from a wider range of perspectives than those 
shown in this paper, (3) change the distribution of risk factors in line with the 
characteristics of certain population sub-groups, (4) analyse the results over varying time 
periods (between 4 and 12 years), (5) separate the general CVD results presented here 
into other CVD categories such as heart disease, myocardial infarction and stroke, and (6) 
examine the health and economic impact of programs that target multiple CVD risk-
factors simultaneously.   
 
However, whilst the model’s methodology is firmly based on cost-effectiveness analysis, 
it is not a substitute for it.   Its two main outputs are to estimate (1) the potential life-years 
saved in a local community following the introduction of CVD prevention programs and 
(2) to provide decision-makers with information on the maximum amount that could be 
spent on those programs within a given CE threshold.  Decision-makers then have to 
make an assessment on whether the maximum amount allowable is realistic given their 
costs and resource constraints.  
 
It should be noted that the three interventions presented in this paper were chosen to 
illustrate the wide range of possible programs that can be modelled.  However, local 
decision-makers could essentially model any preventive program that targets smoking, 
high blood pressure or cholesterol or any combination of these three.  Furthermore, the 
model is capable of estimating the incremental effects of programs that target the same 
risk factor (e.g. compare the impact of two or more alternative quit smoking programs).  
 
 
The model contains a number of assumptions and limitations. First, the impact of each 
preventive intervention is modelled for the primary risk factor only. This may lead to an 
underestimate of the impact because, for example, dietary advice aimed at reducing 
cholesterol levels may also affect blood pressure. Second, only the costs and 
consequences of preventing CVD have been estimated and each intervention may have 
further, non-CVD, impacts. For example, reducing the number of smokers in society 
could impact on lung cancer incidence.  Similarly, some patients whose CVD event is 
prevented may then go on to develop worse (or more expensive) illnesses.  For example, 
for every CVD death prevented, a proportion of the population may go on to develop 
Alzheimer’s disease.   
 
At the outside, this paper aimed to assist decision-makers with three out of the four main 
sources of variation between published studies and the local context.  The fourth source 
that deals with the issue of a locally relevant comparator intervention is not directly dealt 
with in the model. One way of dealing with this source of variation is that local decision 
makers have to choose the published study from which to extrapolate effectiveness 
information carefully.  Ideally, a published study will provide comparisons between two 
(or more) programs that bear relevance to current local practice and to what is being 
considered for implementation.  Often this ideal may not be realised.   For example, the 
published study might be reporting on the effectiveness of having dieticians provide 
advice on how to reduce cholesterol, whereas the local decision maker might be 
considering implementing a dietary advice program delivered by local doctors. 
  
 
If there are significant differences between the comparator used in the published study 
and local practice, the local decision maker will have to make an assessment of the likely 
impact on the study result. There are a number of techniques within the model to assist in 
this assessment.  Firstly, if the published study result is likely to be less effective than a 
local program, the model’s estimation could be considered an underestimate of the health 
and economic impact of the program (e.g. current local practice is known to be less 
effective than the comparator used in the published study).  In this case, decision-makers 
may be satisfied knowing that the envisioned program is likely to deliver more health 
gains than have been estimated.  Secondly, if there is uncertainty about the difference in 
effectiveness between the published result and the local program, a new (lower) CE 
threshold could be entered into the model.  This sets a higher bar for the program by 
estimating a lower feasible expenditure on the intervention for it to remain cost-effective.  
This approach is in line with recommendations made by the NHMRC
4.  Thirdly, the 
model can estimate a range of effectiveness measures to provide a sensitivity analysis.  
The decision-maker will then be provided with a range of feasible expenditures for the 
prevention program.  
 
The model presented can be modified as better evidence on effectiveness and costs 
become available. With better data, the model has the potential to become an increasingly 
useful tool for health care planning and priority setting.  
 
Finally, the model’s estimates are based on the potential savings to the health system 
following the implementation of preventive programs.  However, there is no guarantee 
that such potential savings can be realised. Health services throughout the world face 
considerable demand pressures for their services and therefore any potential savings  
 
                                                
made may go towards meeting some of that unmet demand.  Furthermore, due to 
difficulties in shifting resources from one part to the health care sector to another, local 
decision makers may sometimes face financial disincentives to implement population 
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